Takhzyro (Lanadelumab)

Takhzyro (Lanadelumab-flyo)

Takhzyro

Lanadelumab-flyo

Injection: 300 mg/2 mL (150 mg/mL) solution in a single-dose vial

Shire Pharmaceuticals

Medical Use

Takhzyro, which contains the active ingredient lanadelumab-flyo, is a biologic medication classified as a plasma kallikrein inhibitor (monoclonal antibody). It is used for the prophylactic treatment of hereditary angioedema (HAE) types I and II in patients aged 12 years and older.

The safety and efficacy of Takhzyro in children under 12 years of age have not been established.

Dosage Information:

 Takhzyro is administered as a preventive treatment every two weeks. It is available as a 300 mg/2 mL (150 mg/mL) solution in a single-dose, ready-to-use prefilled syringe.

For patients beginning Takhzyro, the recommended dosage is 300 mg every two weeks. If a patient experiences no attacks for over six months, their healthcare provider may consider adjusting the dosage to 300 mg every four weeks. It is crucial to receive proper training from a healthcare professional before self-administering this injection.